※이 정보는 고수의 추천주식에서 생산한 것이 아닌 외부에서 얻은 정보를 공유하는 것입니다
※제공하는 정보는 투자판단의 참고자료이며, 투자판단의 최종책임은 본 정보를 열람하시는 이용자에게 있습니다
원풍물산(008290) - 美 투자사, ‘렐마다’, 우울증장애(MDD) 치료제 REL-1017 임상3상 개시
미반영 외신)
[원풍물산]
美 투자사, ‘렐마다’, 우울증장애(MDD) 치료제 REL-1017 임상3상 개시
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
as December 07, 2020 8:40am EST
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the first patient has been enrolled in the first Phase 3 clinical trial (RELIANCE I) for the Company's lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder (MDD).
https://www.relmada.com/investors/news-and-events/press-releases/detail/220/relmada-therapeutics-announces-initiation-of-phase-3
정보팀
0
0
0
